J&J Appeals $1.2 Billion Arkansas Risperdal Ruling

Johnson & Johnson appealed an Arkansas judge’s decision to fine the drugmaker $1.2 billion over what state officials said was a misleading marketing campaign for the company’s antipsychotic drug Risperdal.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.